Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Quinolone showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Quinolone showed no clear difference in number of participants experiencing one or more exacerbations… compared with macrolide (low certainty).
1 finding from 1 review
Intervention not reported
Interventions · people with cirrhosis and spontaneous bacterial peritonitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Liver transplantation · people with cirrhosis and spontaneous bacterial peritonitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Ciprofloxacin (2 RCT; 275 participants) · people with cirrhosis and spontaneous bacterial peritonitis
It is very uncertain whether the intervention changes ciprofloxacin (2 RCT; 275 participants) (very low certainty).
1 finding from 1 review
HR 0.93 [0.69, 1.25]
Studies not reported
Very low
Intervention not reported
Cefotaxime (1 RCT; 37 participants) · people with cirrhosis and spontaneous bacterial peritonitis
It is very uncertain whether the intervention changes cefotaxime (1 RCT; 37 participants) (very low certainty).
1 finding from 1 review
HR 0.56 [0.11, 2.28]
Studies not reported
Very low
Intervention not reported
Ciprofloxacin (1 RCT; 35 participants) · people with cirrhosis and spontaneous bacterial peritonitis
It is very uncertain whether the intervention changes ciprofloxacin (1 RCT; 35 participants) (very low certainty).
1 finding from 1 review
HR 0.65 [0.12, 2.72]
Studies not reported
Very low
Intervention not reported
Ceftazidime (No direct RCT) · people with cirrhosis and spontaneous bacterial peritonitis
It is very uncertain whether the intervention changes ceftazidime (No direct RCT) (very low certainty).
1 finding from 1 review
HR 1.15 [0.17, 6.37]
Studies not reported
Very low
Intervention not reported
Amikacin (No direct RCT) · people with cirrhosis and spontaneous bacterial peritonitis
It is very uncertain whether the intervention changes amikacin (No direct RCT) (very low certainty).
1 finding from 1 review
HR 0.76 [0.09, 5.9]
Studies not reported
Very low
Intervention not reported
Cefixime (1 RCT; 38 participants) · people with cirrhosis and spontaneous bacterial peritonitis
It is very uncertain whether the intervention changes cefixime (1 RCT; 38 participants) (very low certainty).
1 finding from 1 review
HR 1.26 [0.26, 6.9]
Studies not reported
Very low
Intervention not reported
Cefonicid (1 RCT; 60 participants) · people with cirrhosis and spontaneous bacterial peritonitis
It is very uncertain whether the intervention changes cefonicid (1 RCT; 60 participants) (very low certainty).
1 finding from 1 review
HR 1.3 [0.52, 3.24]
Studies not reported
Very low
Intervention not reported
Meropenem plus daptomycin (No direct RCT) · people with cirrhosis and spontaneous bacterial peritonitis
It is very uncertain whether the intervention changes meropenem plus daptomycin (No direct RCT) (very low certainty).
1 finding from 1 review
HR 0.64 [0.05, 6.13]
Studies not reported
Very low
Intervention not reported
Ofloxacin (No direct RCT) · people with cirrhosis and spontaneous bacterial peritonitis
It is very uncertain whether the intervention changes ofloxacin (No direct RCT) (very low certainty).
1 finding from 1 review
HR 0.56 [0.09, 2.93]
Studies not reported
Very low
Treatment failure · adults with scrub typhus
It is very uncertain whether doxycycline changes treatment failure compared with tetracycline (very low certainty).
1 finding from 1 review
Serious adverse events · adults and adolescents with scrub typhus
1 finding from 1 review
Treatment failure · adults with scrub typhus
1 finding from 1 review
Resolution of fever within 48 hours · adults with scrub typhus
It is very uncertain whether rifampicin changes resolution of fever within 48 hours compared with doxycycline (very low certainty).
1 finding from 1 review